|
시장보고서
상품코드
2075779
정맥주사용 인간 면역글로불린(pH4) 시장 : 유형별, 질환별, 유통 채널별, 지역별Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type, By Disease Indication, By Distribution Channel and by Region |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
정맥주사용 인간 면역글로불린(pH4) 시장 규모는 2026년에 885억 6,000만 달러fh 추정되며, 2033년까지 2,083억 4,000만 달러에 이를 전망입니다. 2026-2033년 CAGR 13.0%를 나타낼 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 885억 6,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 13.00% | 시장 규모 예측(2033년) : | 2,083억 4,000만 달러 |
시장 역학
주요 기업들이 시장에서 입지를 강화하기 위해 파트너십이나 제휴와 같은 비유기적 성장 전략을 점점 더 많이 채택하고 있는 점이, 예측 기간 동안 시장 성장을 뒷받침할 것으로 예측됩니다. 예를 들어, 2020년 1월, 혈장 유래 생물학적 제제의 제조 및 판매 기업인 ADMA Biologics, Inc.는 비공개 파트너 기업과 5년간의 제조 및 공급 계약을 체결하여, ADMA사의 면역글로불린(IG) 제조 공정에서 얻어지는 혈장 유래 중간 분획을 생산 및 판매하게 되었습니다. 본 계약에 따라 ADMA Biologics, Inc.는 자사 공장에서 분획된 혈장을 독자적인 승인된 제조 공정에 따라 치료용 제품을 개발하는 제3자에게 판매함으로써, 분획된 혈장 1리터당 수익을 극대화하게 됩니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신약 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 세계 정맥주사용 인간 면역글로불린(pH4) 시장의 주요 기업 프로파일을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 시장 내 입지, 유통 전략, 주요 발전 사항, 전략 및 향후 계획입니다.
- 본 보고서에서 도출된 인사이트는 기업의 마케팅 담당자 및 경영진이 향후 의약품 출시, 적응증 확대, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있도록 돕습니다.
- 이 책 '세계의 정맥주사용 인간 면역글로불린(pH 4) 시장' 보고서는 투자자, 공급업체, 제약사, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 정맥주사용 인간 면역글로불린(pH4) 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 정맥주사용 인간 면역글로불린(pH4) 시장 : 유형별(2021-2033년)
제5장 세계의 정맥주사용 인간 면역글로불린(pH4) 시장 : 질환별(2021-2033년)
제6장 세계의 정맥주사용 인간 면역글로불린(pH4) 시장 : 유통 채널별(2021-2033년)
제7장 세계의 정맥주사용 인간 면역글로불린(pH4) 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
AJY 26.07.09Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at USD 88.56 Bn in 2026 and is expected to reach USD 208.34 Bn by 2033, growing at a compound annual growth rate (CAGR) of 13.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 88.56 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.00% | 2033 Value Projection: | USD 208.34 Bn |
Market Dynamics
The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to enhance their market presence is expected to propel the market growth during the forecast period. For instance, in January 2020, ADMA Biologics, Inc., a manufacturer, and distributor of plasma-derived biologics, entered a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA's Immune Globulin (IG) manufacturing process. Under this agreement, ADMA Biologics, Inc. will maximize the revenue per liter of plasma fractionated in its plant by selling the fractioned plasma to a third party to develop their therapeutic products under their own licensed manufacturing processes.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global human immunoglobulin (pH4) for intravenous injection market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, disease indication up-gradation, market expansion, and marketing tactics
- The global human immunoglobulin (pH4) for intravenous injection market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human immunoglobulin (pH4) for intravenous injection market
Detailed Segmentation:
- Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type (Revenue, USD Bn, 2021 - 2033)
- IgG
- IgA
- IgM
- Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Disease Indication (Revenue, USD Bn, 2021 - 2033)
- COVID-19
- Primary Immunodeficiency Disease
- Immune-mediated Thrombocytopenia
- Kawasaki Disease
- B Chronic lymphocytic Leukemia(B-CLL)
- Others
- Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Takeda Pharmaceutical Company Limited
- Baxter
- CSL
- Bayer AG
- Grifols, S.A
- Octapharma Brasil Ltda
- Shanghai RAAS Blood Products Co Ltd
- Hualan Biological Engineering, Inc
- Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc)
- China Resources Boya Bio-pharmaceutical Group Co Ltd
- ADMA Biologics, Inc
- Sinopharm Group Co. Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type, 2021€"2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- IgG
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- IgA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- IgM
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
5. Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Disease Indication, 2021€"2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- Primary Immunodeficiency Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- Immune-mediated Thrombocytopenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- Kawasaki Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- B Chronic lymphocytic Leukemia(B-CLL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
6. Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Distribution Channel, 2021€"2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
7. Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Region, 2021€"2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022€"2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €" 2033, (US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €" 2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Baxter
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CSL
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Grifols, S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Octapharma Brasil Ltda
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Shanghai RAAS Blood Products Co Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hualan Biological Engineering, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- China Resources Boya Bio-pharmaceutical Group Co Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ADMA Biologics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sinopharm Group Co. Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
